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Alpha Interferon Induces High Response
In Patients with Hairy-Cell Leukemia
by Jorge R. Quesada, MD, Department of Clinical Immunology
and Biologic Therapy; James M. Reuben, PhD, Department of
Clinical Immunology and Biologic Therapy; John T. Manning,
MD, Department of Pathology; Evan M. Hersh, MD, Department
of Clinical Immunology and Biologic Therapy; and Jordan U.
Gutterman, MD, Department of Clinical Immunology and
Biologic Therapy
This article is a summary of a paper that first appeared in The
New England Journal of Medicine 310(1): 15-18, January 1984.

The treatment of patients with hairy-cell leukemia remains
controversial, and treatment results have been frequently unsatisfactory. Although splenectomy can occasionally restore
hematologic values to normal, a substantial number of patients
have no response or only a transient one. Chemotherapy
successfully induces remission in only a minority of patients and
is often complicated by severe side effects. Recently, other
treatments, such as allogeneic mononuclear cell transfusions,
nonspecific immunotherapy, and leukapheresis, have improved
hematologic values in these patients; these results, however,
have been temporary or require the use of cumbersome
technology.
Because hairy-cell leukemia is a slow-growing malignancy
usually expressing a 8-lymphocyte phenotype, we conducted a
study to determine whether alpha interferon, which has induced
remission in patients with B-cell neoplasms and slow-growing

tumors, could control hairy-cell leukemia. Results of the study
indicate that alpha interferon may be one of the most effective
and least toxic treatments for patients with this disease.
Methods

Six men and 1 woman, aged 26 to 51 years (median, 39), were
treated. The diagnosis of hairy-cell leukemia was made on the
basis of clinical characteristics and the demonstration of typical
hairy cells in peripheral blood, bone marrow, or tissue specimens.
A tartrate-resistant acid phosphatase stain of bone marrow was
positive in 6 of the 7 patients, and in 3 the diagnosis was further
confirmed by electron microscopy. Five of the 7 patients had
undergone splenectomy (6 to 48 months before alpha interferon
therapy). Two patients had not been treated previously. In all
patients, there was evidence of progressive disease at the time of
enrollment in the study.
Alpha interferon was obtained from the State Serum Institute,
Finnish Red Cross Center, Helsinki, Finland. The material was
partially purified to a specific activity of 1 x 1as units/mg of
protein. All patients received a daily dose of 3 x 1as units
administered by intramuscular injection on an outpatient basis.
A complete remission was defined as: (1) an absence of hairy
cells in the bone marrow aspirate and biopsy specimen; (2) a
value for bone marrow granulocytes above 35%, defined as the
sum of the percentages of myelocytes, metamyelocytes, and
Continued on page 6

Ught photomicrographs illustrate bone marrow biopsy specimens taken from a patient 6 months before alpha interferon treatment (left) (Rx:
1-5-83) and 2 months after treatment (right). Approximately 80% of the cells in the pretreatment specimen photo are hairy cells. (Note the
monomorphous leukemic cell population.) After treatment, the bone marrow has recovered its normal polymorphous composition of
hematopoietic elements (megakaryocytes and erythroid and myeloid cells) as shown; hairy cells in this specimen comprise no more than
20% of the total cell population. (Both hematoxylin-eosin-stained sections X250.) (Photomicrographs were provided by John T. Manning,
MD, Department of Pathology.)

Research of Magnetic DrugDelivery Method Underway
A new method of magnetically targeting high concentrations of
cytotoxic drugs to specific tumor sites is currently being investigated at UT MDAH.
According to Arthur W. Boddie, MD, Department of Surgery,
who heads this project, the method works by incorporating a
cytotoxic drug into magnetized particles or cells and, after
intravenous or intra-arterial injection, targeting these drug-laden
carriers to the tumor site by the use of a powerful electromagnet.
A research electromagnet, specially designed and built by the
J. R. Woodruff Company and the National Electric Coil Company,
was acquired by UT MDAH in 1982 for use of this method in
animal studies. This electromagnet is designed to produce a
6000- to 8000-G magnetic field over a 4-in pole gap. A small
animal can be placed on the ground plane between the magnetic
poles and the drug-laden magnetized particles electromagnetically directed to the tumor site.
The primary advantage of the magnetic targeting method is
that only the tumor is exposed to maximal concentrations of the
cytotoxic drug, thus alleviating the problem of systemic toxicity.
According to Dr Boddie, the method may increase concentration
of a drug at the tumor site by 30% over that achieved with
systemic methods of drug administration.
In the present phase of the project, Dr Boddie is searching for
an effective magnetic drug carrier. In other studies of this
technique, drugs bound to most types of carriers, such as
denatured albumin particles, when injected intravenously, were
taken up by the reticuloendothelial system, thus limiting the use
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Use of the electromagnet, built for magnetic drug-targeting
experiments in animals, is shown. After the rabbit is injected with
cytotoxic-drug-laden magnetized particles, it is placed on the
ground plane between the magnetic poles of the electromagnet.
With a force of 6000 to 8000 G, the electromagnet directs high
concentrations of the drug to the tumor site.

of this method. Working with Christopher Poynton, MD, Department of Hematology, and Christopher Reading, PhD, Departments of Tumor Biology and Hematology, Dr Boddie has found
ghost red blood cells incorporated with cobalt colloid particles to
be possible effective carriers of a cytotoxic drug. " Magnetized
ghost red blood cells should be somewhat less susceptible to
reticuloendothelial uptake than other types of magnetic particles," Dr Boddie said. Uptake by the reticuloendothelial system
will be further diminished by administering compounds that
temporarily block the system, such as dextran. This carrier
method, if successful, should allow the targeting of drugs to any
tumor site.
Ultimately, Dr Boddie hopes to combine magnetic targeting
with regional hyperthermia. " Hyperthermia is synergistic with a
number of chemotherapeutic agents," Dr Boddie explained. "We
plan to target drugs magnetically to the tumor site, then focus
heat into·thEnegion to amplify the-effect. " · · .. ·· ... · ......, .... ·- -· ·
If research of the magnetic targeting technique progresses as
planned, Dr Boddie is hopeful that the method will be used in
patients within 2 to 3 years. Use of this method in patients will
require the construction of a much larger electromagnet.

MDAH Forms Organization
for Staff and Associates
UT M. D. Anderson Associates, a new organization for current
and former staff members, fellows, and residents of UT MDAH
has been formed to convey to organization members the latest
developments in cancer treatment; to recognize distinguished
achievements of current and former staff members, fellows, and
residents; and to provide members with a forum for dialogue.
For more information and an application form, please contact
UT M. D. Anderson Associates, HMB Box 223, 6723 Bertner,
Houston, Texas 77030, (713) 792-8573.
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Daily Fluoride Routine Prevents Radiationand Drug-Induced Caries in Cancer Patients
by Terence J. Fleming, DDS, Department of Dental Oncology
This article is a summary of a paper that first appeared in Current
Problems in Cancer: Dental Oncology VII (10): 37-41, April 1983.
For many years clinicians have observed the damaging effects
of cancer therapy on the oral structures. Patients receiving
irradiation to the head and neck region experience a marked
decrease in salivary secretion. This permanent radiation-induced
xerostomia has been found to be significant in producing extreme
susceptibility to caries. Salivary secretion is also suppressed
temporarily in patients receiving the antiemetic medications often
prescribed during chemotherapy.
To alleviate the problem of caries in high-risk patients at UT
MDAH, a strict oral hygiene program involving the daily topical
application to the teeth of a fluoride gel has been established.
This program has proven to be highly effective in patients with
radiation- or drug-induced xerostomia.
The need for such a program was made clear after several
studies of the effects of radiation on the oral structures of head
and neck cancer patients at UT MDAH. In one study a dose of
200 rad per day to all major salivary glands was found to cause a
decrease in the salivary flow rate of 57% after five treatments (1
week), a decrease of 76% after 30 treatments (6 weeks), and a
continued progressive decrease that resulted (3 years after
completion of radiation therapy) in a flow rate of 5% of the
pretreatment flow rate. Another UT MDAH study demonstrated a
100-fold increase in the concentration of a caries-associated
microbe, Streptococcus mutans, 30 months after irradiation.
The same investigation studied the effectiveness of a caries
prevention program consisting of daily oral hygiene and topical
1 % sodium fluoride (NaF) application. The patients were
randomized into three groups: (1) those having oral hygiene and
daily topically applied 1% NaF; (2) those on an oral hygiene
regime, receiving daily topically applied 1% NaF, and having a
restricted sucrose diet; and (3) those on an oral hygiene regime
and using a nonfluoride-containing gel. During the first posttreatment year, 81 % of cases of caries occurred in patients not
receiving the fluoride gel. Essentially no differences were observed between the group receiving fluoride gel only and the
group randomized to receive the fluoride plus the restricted
sucrose diet. These excellent clinical results, using 1% NaF gel to
prevent radiation caries, have been authenticated recently.
Meanwhile, continuous fluoride investigations have shown the
additional plaque-inhibition benefit of stannous fluoride (SnF2 ).
The caries prevention program presently used at UT MDAH
involves the daily topical application of a 0.4% SnF2 gel combined
with strict oral hygiene procedures. Patients are encouraged to
brush after each meal. Once daily, after a thorough brushing,
flossing, and rinsing, patients apply the 0.4% SnF2 gel to the
teeth for a minimum of 5 but preferably 1O minutes by means of
Vol. 29, No. 2

custom-fabricated polypropylene fluoride carriers. After fluoride
application, the patients swish the accumulated saliva and
residue gel for approximately 1 minute and then empty their
mouths. The patients do not disturb the applied fluoride film by
further rinsing, drinking, or brushing for 30 minutes.
The 0.4% SnF2 gel, which is available commercially (GelKam,
Scherer Laboratories, Inc., Dallas) has a pH of 3.2. Although this
Continued on page 8
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Department of Pharmacy

Sixth Annual Pharmacy
Symposium
On Cancer
Chemotherapy
October 7-10, 1984
Shamrock Hilton Hotel
Houston, Texas
Chairpersons: William H. Puckett, Jr, MS, M6A, RPh,
Department of Pharmacy, and Sharon Bronson, MS, RPh,
Department of Pharmacy
This symQOsium is designed to present principles of ·
cancer patient care to the pharmacist and allied health
professional. Topics for discussion include treatment of
patients with AIDS and Kaposi's sarcoma, new
chemotherapeutic agents, the management of infection,
and chemotherapy for patients with lung cancer.
For registration information, write or call the Office of
Conference Services, HMB Box 131, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.
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Cyclotron Provides Fast-Neutron Therapy

for Patients with Radioresistant Tumors

one containing an isocentric-head delivery system and the other
a horizontal-beam delivery system. The two rooms are encircled
by 7-ft-thick reinforced concrete walls that absorb atomic parti
cles.
The isocentric-head delivery system, used exclusively for
patients, is a special feature of the UT MDAH cyclotron,
according to James A. Marbach, PhD, Departments of Physics
and Clinical Radiotherapy, a clinical physicist involved in patient
treatment with the neutron beam. The rotating head enables the
radiotherapist to position the treatment beam at a variety of
angles around the patient. "The isocentric head has been
available for conventional radiotherapy equipment for many
years, but its use with a machine of this power is especially
advantageous," he said.

Use of the cyclotron's isocentric-head delivery system for fast
neutron therapy is demonstrated. The isocentric head, used
exclusively for treatment, is able to rotate 200° and thus deliver
the fast-neutron beam to almost any site of disease.
UT MDAH is now operating the first U.S. cyclotron specifically
designed for cancer therapy and research. The new cyclotron not
only provides fast-neutron therapy for patients with tumors
resistant to conventional radiotherapy (x-ray or cobalt-60) but
also produces radionuclides to aid in cancer diagnosis and
research.
According to Lester J. Peters, MD, head of the Division of
Radiotherapy, the cyclotron was installed because of the favor
able results of a pilot study conducted at Texas A & M University
between October 1972 and February 1980. UT MDAH research
ers, who used the Texas A & M variable-energy cyclotron for
neutron treatment of cancer patients, found fast-neutron therapy
to be highly effective in controlling disease at various sites.
Encouraged by these results, UT MDAH and The University of
Texas Medical Branch at Galveston cooperatively initiated the
building of a neutron therapy facility at UT MDAH in 1977. Unlike
other cyclotrons in the U.S. designed primarily for research in
physics and chemistry, the UT MDAH cyclotron, completed in
September of last year, is the first in the nation designed
specifically for fast-neutron therapy and isotope production.
The cyclotron is a charged-particle, negative-ion accelerator
that produces a high-energy neutron beam by bombarding a
beryllium target with 42 MeV protons at a current up to 200 µA.
The beam is extracted into one of five beam lines with target
areas housed in three rooms; remotely controlled carbon strip
ping foils are used to direct the beam. A fixed-energy, 26-MeV
port is provided for radioactive gas production; a fixed-energy 42MeV port and a 11- to 42-MeV variable-energy port are provided
for liquid and solid radioisotope production. The target area for
these ports is housed in an isotope-production room. There are
two fixed-energy 42-MeV ports provided for two therapy rooms:

4

According to Moshe Maor, MD, Department of Clinical Ra
diotherapy, clinical director of the neutron therapy program, one
of the principal reasons for the effectiveness of fast-neutron
treatment is that, unlike photons used in conventional ra
diotherapy, fast neutrons can more easily kill tumor cells that
have a poor oxygen supply. These cells, generally found in large
solid tumors that have outgrown the blood vessel network, are
more radiosensitive to the neutron beam because of its pattern of
energy deposition. "The neutron blazes a path of destruction
through the tumor cells, whereas the photon has a skip pattern of
injury and, therefore, is less effective against dense unoxygenated tumors," Dr Peters explained.
The more powerful neutron beam is also effective because,
unlike other forms of radiotherapy, it causes almost irreparable
cell damage. In addition, the neutron beam is effective throughout
the cell cycle. "It is not as dependent as other forms of
radiotherapy on catching the cancer cell at specific, more
radiosensitive stages in the cell-division cycle," Dr Maor said.
Nevertheless, neutron therapy is preferable to .conventional
forms of radiotherapy only in selected patients, according to Dr
Peters. Patients with tumors that have good repair capacity, are
slow growing, are poorly oxygenated, or are resistant, for any
reason, to conventional radiation are most likely to benefit from
fast-neutron treatment. Those patients with soft tissue and bone
sarcomas, advanced rectal, prostate, bladder, and uterine can
cers, pancreatic and stomach cancer, kidney cancer, advanced
head and neck cancers (especially of the salivary glands and
thyroid), and some lung cancers are currently being accepted for
fast-neutron treatment. Fast-neutron treatment, however, cannot
be used to control disease at a site that has been previously
irradiated by conventional means.
The side effects of neutron therapy are qualitatively similar to
those of conventional radiotherapy. Irritation of the skin and
mucous membrane or lining of organ tissue may occur soon after
treatment. Gradual thickening or fibrosis of deeper tissue may
occur months later. Although acute reactions are rare, neutron
therapy may cause more severe late effects than x-ray or cobalt60.
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The cyclotron facility floor plan
illustrates the cyclotron, its five
beam lines, and three target
areas (left side), housed in two
treatment rooms and an isotopeproduction room. Offices and laboratories (right side) for personnel
involved in cyclotron operations
are included in the facility.

isotope with a short half-life, for tumors that can not be surgically
The cyclotron also greatly facilitates diagnosis and research
removed or treated by other means.
with its isotope-producing capability. According to Roy S. Tilbury,
PhD, Department of Internal Medicine, who heads the
To handle the high levels of radioactivity associated with the
isotope program, a "hot" laboratory designed for processing
radioisotope production program, the cyclotron makes isotopes
of elements naturally occurring in the body, such as carbon,
radioactive materials is under construction. Radioactive isonitrogen, and oxygen, for use in quantitative biochemistry. The
topes will be transported automatically through special tubing
cyclotron produces a high-energy proton beam that strikes the
between the cyclotron facility and the "hot" laboratory.
nucleus of a common element, transforming the element into an
According to Dr Peters, the UT MDAH cyclotron is a prototype
unstable isotope. By labeling naturally occurring elements with
machine for other research hospitals. Three other U.S. hospitals
their corresponding isotopes and using these isotopes as tracers,
have obtained grants to build cyclotrons with similar capacities.
more accurate measurements of these elements in the body can
"Although the cyclotron is not a panacea," Dr Peters said, "its
be obtained. Isotopes made of elements foreign to the body, such
potential for therapy and isotope-producing capability offer excitas technetium-99, can never be regarded as true chemical
ing possibilities for cancer treatment and research."
tracers; they are not able to be totally metabolized with the
(Physicians desiring additional information should write or call
natural element to which they are attached. "With cyclotronMoshe Maor, MD, Department of Clinical Radiotherapy, MDAH
produced isotopes, however, we can label oxygen with oxygenBox 276, The University of Texas M. D. Anderson Hospital and
15, for example, and measure oxygen metabolism in the brain,"
Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Dr Tilbury said. "This is important because oxygen and glucose
Texas 77030 (713) 792-3410.-ED)
are the only two metabolites the brain uses."
Presently, Dr Tilbury is studying the use of cyclotron-produced
The University of Texas
M. D. Anderson Hospital and Tumor Institute
isotopes for measuring pH in tissue. "We know that tumor tissue
at Houston
has a lower pH than normal tissue. If we can develop an agent
Department of Nursing
that can measure pH," he explained, "it might give useful
diagnostic information and aid in the selection of treatment."
Oncology Nursing Conference VI
Cyclotron-produced isotopes will eventually be used at UT
MDAH to perform receptor-site assays as well. For example,
- - -----Mesttadiol can be labelea-with--fadioisotopes and-measur:ed-i 1~ ·1¥U-- -- -+-- - - -- -~eptember-1-2'=
-+4-,-"H-l!H4-- - - - - --i---to determine whether a breast tumor is or is not estrogen
dependent. This assay now must be performed in vitro with a
Hyatt Regency Hotel Downtown
Houston, Texas
tissue sample.
Finally, cyclotron-produced isotope implants will be used for
therapy. At present, the most common radioactive materials
Chairperson: Anita K. Verges, RN, BSS, Department of
Nursing
implanted in tumors are radioactive "gold seeds," irradiated
pieces of gold sealed in platinum tubing, that emit a high-energy
For registration information, write or call the Office of
radiation to which both the patient and surgeon are exposed.
Conference Services, HMB Box 131, The University of
Another isotope used for treatment, iodine-125, has low-energy
Texas M. D. Anderson Hospital and Tumor Institute at
radiation but a long half-life, which reduces the isotope's theraHouston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.
peutic efficacy. Though experimental, Dr Tilbury has devised a
plan to make cesium-131 , a low-energy cyclotron-produced
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TABLE 1. Clinical Characteristics and Bone Marrow Values in Patients with Hairy-Cell Leukemia*

Pt. No.
Sex/Age

1
2
3
4
5
6
7

M/39
M/26
M/34
M/46
F/47
M/51
M/31

Prior
Response
Splenectomy To IFNo:

+
+
+
+
+

CR
CR
CR
PR
PR
PR
PR

Post-treatment
Bone Marrow

Pretreatment
Bone Marrow

HC

Aspirate
GR

%
38
17
32
39
53

%
14
14
15
3
6
Dry

48

10

B-Cell
Markers

+
ND
ND

+
ND
ND

+

Treatment
Duration
(Mo.)t

Biopsy
HC*

HC

Aspirate
GR
B-Cell
Markers

Biopsy
HC*

%
28
33
17
72
30
48
42

%
0
0
0
0
5
4
18

%
62
40
64
46
64
61
60

%
0
0
0
3
12
19
10

+
+

>6
>8
>6
>8
>6
>7
>10

• Abbreviations are as follows: IFNa = alpha interferon, HC = hairy cells, GR= granulocytes, CR= complete remission, ND = not done, and PR = partial remission .
tPatients were entered into study at different times; response in all patients is sustained by continued treatment.
:j:The percentage of hairy cells in biopsy specimens represents the product of the percentage of hairy cells and bone marrow cellularity.

Hairy-Cell Leukemia
Continued rrom page 1

neutrophils; (3) a normal distribution of cell membrane markers of
bone marrow mononuclear cells, as determined by the use of
fluorescein-labeled monoclonal antibodies; and (4) restoration of
the following values: the hemoglobin level to 12 g/dl or more, the
absolute neutrophil count to 1500 or more cells/µI, and the
platelet count to 100,000 or more cells/µI.
A partial remission was defined as: (1) a decrease in the hairycell leukemia infiltrate of more than 50% from pretreatment
values, (2) a value of bone marrow granulocytes above 35%, and
(3) restoration of the peripheral-blood values as indicated above.

Results
Table 1 shows the clinical characteristics and bone marrow
values of the patients. All patients responded to treatment; 3 had
a complete remission, and 4 had a partial remission.
A decrease in the proportion of hairy cells was documented in
the bone marrow aspirates from all 7 patients. In 6 patients, the
proportion of hairy cells was 5% or less within 8 to 12 weeks after
the initiation of treatment. Serial bone marrow biopsies confirmed
the absence of hairy cells in the 3 patients who had a complete
remission (Table 1). Studies of cell membrane markers in the
bone marrow were performed before treatment in 3 patients and
after treatment in all patients. Pretreatment specimens showed a
predominance of cells with the B phenotype (cells positive for
surface immunoglobulins and la and B1 antigens). Posttreatment specimens showed a normal phenotypic distribution of
mononuclear cells in the 3 patients who had a complete
remission and in 2 of the 4 with a partial remission. The other 2
patients continued to have an abnormal number of cells with the
B phenotype.

Concurrently, a marked increase in the proportion of bone
marrow granulocytes was seen in all patients (Table 1). Before

6

treatment, the proportion of granulocytes in the bone marrow
ranged from 3 to 15% (median , 14%). After treatment, the range
of the proportion of granulocytes was 40 to 64% (median , 61 %) .
In Patient 6, the pretreatment bone marrow aspirates were
repeatedly dry; the bone marrow cellularity increased after
treatment, and the proportion of bone marrow granulocytes
reached a maximum of 61 % by the 20th week of therapy. In
addition, bone marrow monocytes (0.5 to 6%) were identified in 5
patients who had previously lacked them. The effects of alpha
interferon on the bone marrow differential count were seen within
the first 2 to 4 weeks after initiation of treatment.
A rise in the level of hemoglobin occurred in all 6 patients with
anemia (Table 2). Pretreatment values ranged from 9.3 to 12.9
g/dl (median, 11.0 g/dl), whereas post-treatment levels ranged
from 12.6 to 14.5 g/dl (median, 14.4 g/dl) in the absence of
transfused blood products. All patients had an increase in
circulating granulocytes, including patients with severe
granulocytopenia before treatment. In 3 patients, granulocyte
counts of 1500 or more cells/µI were reached within 8 weeks. In
all 5 patients with leukopenia, increments in the white cell counts
occurred more gradually. In one patient with leukocytosis, alpha
interferon reduced the leukocyte count to the normal range and
caused an attendant rise in the granulocyte count. Of 4 patients
with thrombocytopenia, 2 had normal platelet counts within 3
weeks after the initiation of therapy, and the other 2 within 8
weeks. Alpha interferon did not adversely affect the platelet count
in 3 patients with normal pretreatment values.
Remissions were sustained with daily administration of alpha
interferon in 4 patients and with doses given 3 times per week in 3
patients who had been treated for longer than 6 months.
Treatment with alpha interferon was well tolerated by the
majority of patients. All patients exhibited a transient influenzalike syndrome that has been described in other cancer patients
treated with alpha interferon. Six patients reported slight fatigue
and anorexia, but all 6 continued their normal activities; no
notable weight loss occurred. One patient reported severe
fatigue, asthenia, and apathy, symptoms that were reversed by
temporary discontinuation of treatment.
April-June 1984
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lymphoma. This suggests that the effect of alpha interferon may
somehow be related to the interleukin 2 membrane receptors .

TABLE 2. Peripheral Blood Values in Patients with
Hairy-Ce/I Leukemia*

Pt.

Pretreatment
No.
Peripheral Blood
HG WC Neutro- Platephils
lets
cells x 103/µI
g/dl
2
3
4
5
6
7

9.7 2.9
12.9 8.0
11.0 2.4
11.0 3.1
10.3 1.8
9.3 1.4
15.5 29.4

0.2
1.4
1.2
0.2
0.5
0.4
2.0

71
342
263
148
85
116
196

Post-treatment
Peripheral Blood
HG WC Neutor- Platelets
phils
g/dl
cells x 103/µI
14.4
14.5
14.5
14.4
12.6
13.3
14.9

5.5
8.4
4.2
3.8
3.6
2.3
6.8

4.1
2.3
2.6
2.0
2.9
1.8
5.6

444
350
368
314
531
209
299

*Abbreviations are as follows: HG= hemoglobin, WC= white cells.

Two patients with a history of repeated infections contracted
infections within the first 2 weeks after initiation of therapy (lobar
pneumonia and soft tissue infection). One other patient had a
miliary pulmonary infiltrate of probable fungal origin, which
responded to the administration of ketoconazole. No infections
occurred in any patient after the first 8 weeks of treatment.

Discussion
In our experience, no other form of treatment has been so
consistently effective in achieving remissions in patients with
hairy-cell leukemia. When treatment was initiated, all patients
had evidence of slowly progressive disease, but none had severe
pancytopenia. Whether alpha interferon can induce a similar
tumor response in more advanced stages of the disease is not
known. Also, the small number of patients in this study and the
short time to follow-up preclude statements regarding the longterm efficacy of the treatment or its impact on survival.
The mechanisms responsible for the antitumor activity of alpha
interferon and the ensuing benefit in the hematologic values are
probably multifactorial. A direct antitumor effect on the malignant
cells would allow repopulation of the bone marrow by displaced
or inhibited normal blood cell precursors. Alpha interferon has
been shown to have a potent antiproliferative effect on lymphoma
cell lines in vitro, as well as antitumor effects in patients with Bcell or T-cell neoplasms. In this regard as mentioned above, hairy
cells often express a B-lymphocyte phenotype. One other intriguing possibility is that alpha interferon induces differentiation of the
malignant cells; it is known to induce differentiation oJ a leukemic
cell line in vitro.
The high sensitivity of hairy-cell leukemia to alpha interferon
contrasts with the lower response rate of other B-cell neoplasms,
such as nodular lymphocytic lymphoma and multiple myeloma.
This high sensitivity may be due to the presence of the Tac
antigen, which has been recently described in hairy-cell leukemia
and which may indicate a unique stage of B-cell differentiation.
The Tac antigen, found in T cells, is associated with the receptor
for interleukin 2. A similar rapid tumor response to alpha
interferon has been reported in patients with cutaneous T-cell
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Interestingly, the hematologic effect of alpha interferon in
patients with other malignant conditions is characterized by a
decrement in the peripheral leukocyte and granulocyte counts, as
well as a steady decrease in the hematocrit. In vitro test results
have shown that alpha interferon blocks granulopoietic differentiation of committed bone marrow colony-forming units. The
prompt hematologic effects induced by alpha interferon in patients with hairy-cell leukemia suggest the existence of a functional reserve of cell progenitors, which are influenced to proliferate as a result of treatment. This effect has not been observed in
patients receiving other types of treatment.
Numerous biologic effects on the immune system have been
ascribed to alpha interferon, some of which may also have
influenced the results of our study. For example, alpha interferon
is able to activate cytotoxic cells of the immune system; this
system is severely impaired in patients with hairy-cell leukemia.
Because the synthesis of alpha interferon in the body has been
found to be influenced by a chromosome X-linked locus in mice, it
is tempting to speculate that patients with hairy-cell leukemia,
which occurs predominately in men, have a chromosome Xrelated deficiency of alpha interferon; this condition may be
alleviated by exogenous interferon administration.
In support of this idea, male patients who have Epstein-Barr
virus infection with chromosome X-linked immunodeficiency have
been found to have a high incidence of B-cell lymphoma. EpsteinBarr virus has been associated with the pathogenesis of hairycell leukemia.
Finally, there is increasing evidence that the activation or
rearrangement of oncogenes is important in the pathogenesis of
B-cell neoplasms and other tumors. Recently, an oncogene
coding for a growthlike factor has been described in avian and
human B-cell lymphoma. A related gene may also be involved in
hairy-cell leukemia. Interferon has been shown to suppress the
expression of the protein product of at least one oncogene,
suggesting that this mechanism may also have been involved in
the antitumor effects observed in our patients.
Regardless of the mechanism, the rapid improvement that
occurs in the absence of adverse side effects suggests that
interferon is therapeutic in patients with hairy-cell leukemia,
including those in whom splenectomy is not desirable. We used a
partially pure preparation of alpha interferon that contained
numerous interferon subtypes. We hope to confirm our results
with purified species of alpha interferon.
Further stuaies of the mechanisms of action of interferon in
hairy-cell leukemia may offer a greater understanding of the
disease and increase our knowledge of how interferon works.
Hairy-cell leukemia, thus, should provide a disease model for
more in-depth study of the diverse biologic effects of interferon, which may have application in the treatment of other
malignancies.
(Physicians desiring additional information should write or call
Jorge R. Quesada, MD, Department of Clinical Immunology and
Biologic Therapy, MDAH Box 55, The University o.f Texas M. D.
Anderson Hospital and Tumor Institute at Houston, 6723 Bertner
Avenue, Houston, Texas 77030 (713) 792-3527.-ED)
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Fluoride Routine
Continued from page 3

is more acidic than the 1% NaF, the soft tissue irritations
experienced by patients during radiation therapy and sometimes
even into the postradiation period have been a problem for less
than 2% of our patients.
In evaluating patients and categorizing those who are in the
high-risk caries-susceptible group, many clinicians fail to consider the overall contributions of the various salivary glands to the
total salivary secretion. Frequently, the decision as to the
necessity of placing patients on a fluoride program is based
solely on the relative radiation effect on the parotid glands.
Investigations have shown this to be incorrect. Under mechanical
stimulation (mastication), the contribution of the parotid glands
constitutes 58% of the whole saliva; 33% of saliva is supplied by
the submandibular glands, 1.5% by the sublingual glands, and
7.5% by the minor accessory salivary glands. The contribution to
the total salivary secretion from the parotid glands during the
resting state (other than mastication or sleep) is 21.5%; the
submandibular glands contribute 71 %; the sublingual glands
2.0%; and the minor accessory glands 6.5%. The parotid
secretion during sleep is zero; the submandibular gland secretion
constitutes 72%; the sublingual glands provide 14%; and the
minor accessory glands another 14%.
Clinical observations indicate that patients treated with radiation to the upper neck fields (submaxillary triangle area), such as
the postlaryngectomy patient or the patient with a lesion at the
base of the tongue or floor of the mouth, have the greatest
permanent degree of xerostomia. As expected, such patients
who do not comply with the preventive caries program manifest
the greate~t degree of the typical rampant caries pattern associated with the loss of salivary protection.
Patients undergoing cancer therapy are highly caries susceptible, either temporarily from drug-induced xerostomia or permanently from radiation-induced xerostomia. Clinical experience
has shown that fluoride treatments professionally applied at
irregular intervals do not provide the necessary degree of
protection for these patients. It is essential that this special group
of patients follow a continuous daily self-applied topical fluoride
program, combined with a high degree of daily oral hygiene and
regular professional dental care.
(Physicians desiring additional information should write or call
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Terence J. Fleming, DDS, Department of Dental Oncology,
MDAH Box 9, The University of Texas M. D. Anderson Hospital
and Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030 (713) 792-6945.-ED)

The University of Texas System Cancer Center
M. D. Anderson Hospital and Tumor Institute
at Houston
and
The University of Texas
Health Science Center at Houston

Conference on AIDS:
Diagnosis and
Management
June 8-10, 1984
Warwick Post Oak Hotel
Houston, Texas
Chairpersons: Guy R. Newell, MD, Department of Cancer
Prevention, and Peter W. A. Mansell, MB BCH, FRCS,
Department of Cancer Prevention
Designed primarily for physicians, the conference will
address the treatment of acquired immune deficiency
syndrome and related infections, malignancies, and
underlying abnormalities.
For registration information, write or call the Office of
Conference Services, HMB Box 131, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.

April✓une 1984

